Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ripretinib for Preoperative GIST After Imatinib Failure
NCT05132738Unknown
- Sponsor
- Renji Hospital
- Start
- Aug 2021
- Primary completion
- Nov 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label, single-arm trial of ripretinib in gastrointestinal stromal tumor (GIST), sponsored by Renji Hospital. Primary endpoint: No Evidence of Disease Rate. Status: unknown.
02
Drugs
ripretinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT05132738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05132738.